Skip to main content

Table 3 Achievement of Secondary end point according to LN biopsy classes

From: Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial

Secondary end points achieved CYC MMF p-value Odds ratio Confidence Interval
No. (%) No.%
Baseline biopsy
Class III / III + V
3 (60%) 3 (42.9%) 1.000 0.50 0.048–5.152
Baseline biopsy
class IV / IV + V
11 (68.8%) 11 (78.6%) 0.689 1.67 0.318–8.741